Pending — not yet graded
“Bullish on Indian pharmaceutical stocks, specifically Divi's Laboratories, for 2026 and for investors with a one-year-plus horizon. He considers Divi's a reasonable buy from current levels, citing improving global demand and the company's strong positioning in custom synthesis and APIs.”
Sudip Bandyopadhyay’s track record: 8 graded calls · 95% CI 14–69%
Reliance IndustriesBullishCalled 07 Jan 2026
This call hasn't reached its evaluation window yet — the HIT/MISS verdict will appear here once it's graded against real price data. Save it above to find it again from your profile.
Read the original articleSee Sudip Bandyopadhyay’s full track record